186 patienter blev randomiseret til at få docetaxel (100 mg/ m2) med eller uden trastuzumab.
One hundred eighty six patients were randomized to receive docetaxel (100 mg/ m2) with or without trastuzumab; 60% of patients received prior anthracycline-based adjuvant chemotherapy.